Hi guys, this might be old news, but doing a bit of research today I came across this analysis by Edison Research of Destiny Pharma in the UK.
https://www.edisongroup.com/wp-content/uploads/2018/10/Destiny-Pharma-Destiny-beguiles-1.pdf
Destiny have just finished a Phase 2 trial (results Q1) of a drug similar to ours for prevention of post operative infections (yes i know, competition).
I found the analysis interesting because it gives some assumptions of potential earnings if all goes well.
Sorry if this has been posted before.
BOT - Anything but charting, page-1441
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.5¢ | $1.940M | 6.061M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 470483 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 33000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |